====== Isaac Bogoch ======

{{ ::isaac-bogoch-180x180.jpeg?200|}}

Dr. **Isaac Bogoch**, MD, SM is a Canadian [[infectious diseases]] specialist based in [[canada:Ontario:Toronto]], [[canada:Ontario]].

===== Education =====

Bogoch completed medical school and Internal Medicine residency training at the [[University of Toronto]], and then specialized in Infectious Diseases at [[Harvard University]]. He holds a Masters Degree in Clinical [[Epidemiology]] from the [[Harvard T.H. Chan School of Public Health]], and has completed fellowships in both Tropical Infectious Diseases and HIV care.

===== Career and Affiliations =====

Bogoch has been a presenter at events for the [[British Columbia Pharmacy Association]] (BCPhA).((//Agenda and Speakers.// BC Pharmacy Association. Retrieved May 22, 2022, from https://web.archive.org/web/20220523043059/https://www.bcpharmacy.ca/conference/agenda-speakers))

==== University of Toronto ====

Bogoch is an associate professor in the Department of Medicine at the [[University of Toronto]].((//Our Partners.// Ontario COVID-19 Science Advisory Table. Retrieved May 9, 2022, from https://web.archive.org/web/20220509143427/https://covid19-sciencetable.ca/our-partners/)) ((//Infectious Diseases Faculty Member.// (2022). University of Toronto. https://archive.ph/lZKZD))

==== Toronto General Hospital ====

Bogoch is an infectious diseases consultant at [[Toronto General Hospital]] under the [[University Health Network]] with a focus on [[tropical diseases]], [[HIV]], and general infectious diseases.((//Our Partners.// Ontario COVID-19 Science Advisory Table. Retrieved May 9, 2022, from https://web.archive.org/web/20220509143427/https://covid19-sciencetable.ca/our-partners/))

==== Ontario COVID-19 Science Advisory Table ====

Bogoch is a member of the Modelling Consensus Table of the [[Ontario COVID-19 Science Advisory Table]].((//Our Partners.// Ontario COVID-19 Science Advisory Table. Retrieved May 9, 2022, from https://web.archive.org/web/20220509143427/https://covid19-sciencetable.ca/our-partners/))

==== Ontario COVID-19 Vaccine Distribution Task Force ====

Bogoch was a member of the [[Ontario COVID-19 Vaccine Distribution Task Force]] under the [[Solicitor General of Ontario]] and the [[Ontario Minister of Health]].((//COVID-19 Vaccine Distribution Task Force.// (2020, December 15). Wayback Machine; Public Appointments Secretariat. https://archive.ph/m8Q0t)) ((Lempert, R. P. A. (2021, May 12). //Meet Issac Bogoch: Another UofT “Expert” Pushing Experimental Vaccines On The Public.// [[Canuck Law]]. https://archive.ph/MgPAN)) His term was December 4, 2020 to August 31, 2021.
==== Consulting ====

Bogoch was hired by the [[NHL Players' Association]] to review their [[COVID-19]] safety protocols.((Bogoch, I. (2021). //Declaration of Interest.// https://web.archive.org/web/20220509143453/https://covid19-sciencetable.ca/wp-content/uploads/2020/10/Declaration-of-Interest_Modeling-Consensus-Table_Isaac-Bogoch.pdf)) ((Campbell, K. (2020, April 27). //NHL’s summer play plan has “real traction” says infectious diseases expert. The Hockey News.// https://archive.ph/QZG2U))

He also received consulting fees from [[BlueDot]], the Canadian [[artificial intelligence]] company that claimed responsibility for being first in the world to detect the initial spread of [[SARS-CoV-2]] in [[china:Wuhan]], [[China]] in December 2020. Indeed, Bogoch is the lead author on a study titled //"Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel"// with the BlueDot team.((Bogoch, I. I., Watts, A., Thomas-Bachli, A., Huber, C., Kraemer, M. U. G., & Khan, K. (2020). //Pneumonia of Unknown Etiology in Wuhan, China: Potential for International Spread Via Commercial Air Travel.// Journal of Travel Medicine, 27(2). https://doi.org/10.1093/jtm/taaa008)) The study was submitted to the [[Journal of Travel Medicine]] on January 8, revised January 9, and accepted January 10, 2020.

===== Research =====

==== Zika ====

In 2016, Bogoch published a paper on the [[Zika]] virus funded by the [[Canadian Institutes of Health Research]] (CIHR), [[National Institutes of Health]] (NIH), [[Wellcome Trust]], [[Bill & Melinda Gates Foundation]], and the [[Research and Policy for Infectious Disease Dynamics]] (RAPIDD) program of the [[Fogarty International Center]]. RAPIDD is co-funded by the [[Science & Technology Directorate]] of the [[U.S. Department of Homeland Security]].((Bogoch, I. I., Brady, O. J., Kraemer, M. U. G., German, M., Creatore, M. I., Kulkarni, M. A., Brownstein, J. S., Mekaru, S. R., Hay, S. I., Groot, E., Watts, A., & Khan, K. (2016). //Anticipating the international spread of Zika virus from Brazil.// The Lancet, 387(10016), 335–336. https://doi.org/10.1016/S0140-6736(16)00080-5))

==== COVID-19 ====

Bogoch received grant funding from the [[Canadian Institutes of Health Research]] (CIHR) to "study the global spread of [[COVID-19]]".((Bogoch, I. (2021). //Declaration of Interest.// https://web.archive.org/web/20220509143453/https://covid19-sciencetable.ca/wp-content/uploads/2020/10/Declaration-of-Interest_Modeling-Consensus-Table_Isaac-Bogoch.pdf)) ((Fauver, J. R., Petrone, M. E., Hodcroft, E. B., Shioda, K., Ehrlich, H. Y., Watts, A. G., Vogels, C. B. F., Brito, A. F., Alpert, T., Muyombwe, A., Razeq, J., Downing, R., Cheemarla, N. R., Wyllie, A. L., Kalinich, C. C., Ott, I. M., Quick, J., Loman, N. J., Neugebauer, K. M., & Greninger, A. L. (2020). //Coast-to-Coast Spread of SARS-CoV-2 during the Early Epidemic in the United States.// Cell, 181(5), 990-996.e5. https://doi.org/10.1016/j.cell.2020.04.021)) 

One such grant was awarded on February 1, 2020.((Treasury Board of Canada Secretariat. (2020, February 1). //Operating Grant: COVID-19 - Transmission dynamics/animal host/modeling.// Open Government Portal. https://archive.ph/Uf9SC)) The program called on applicants to:

  * "Contribute to the global response to the 2019-nCoV outbreak; 
  * Enhance local, national and/or international collaborative efforts to mitigate the rapid spread of 2019-nCoV and its potential negative consequences; 
  * Strengthen the understanding of the impact of 2019-nCoV on individuals and communities; and
  * Provide evidence to inform clinical and public health response, and/or decision-making and planning at national and international levels."